AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8174440 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (60 mg daily)
Number of subjects: 0
Study 8174440 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 8174440 — intervention group
Group type: COMPARATOR
Intervention: Pancreatin monotherapy
Number of subjects: 0
Study 3359658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 13
Study 3359658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 29246532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanoia platform access after minimal training
Number of subjects: 320
Study 29246532 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study 27219520 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-length renal artery ablation
Number of subjects: 47
Study 27219520 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal renal artery ablation
Number of subjects: 47
Study 24942611 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress positron emission tomography (PET) with regadenoson
Number of subjects: 50
Study 24942611 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 50
Study 22318648 — intervention group
Group type: EXPERIMENTAL
Intervention: Free consumption of fruits and vegetables (less than 75 mg phenylalanine per 100 g)
Number of subjects: 14
Study 22318648 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (accounting for protein from fruits and vegetables)
Number of subjects: 14
Study 20505547 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE)
Number of subjects: 10739
Study 20505547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study 18783399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m²
Number of subjects: 54
Study 18783399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m²
Number of subjects: 54
Study 16995860 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg twice daily for 6 weeks
Number of subjects: 2
Study 16995860 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2
Study 12877250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm extraction 24 hours before ovum pickup
Number of subjects: 54
Study 12877250 — intervention group
Group type: COMPARATOR
Intervention: Sperm extraction on the day of oocyte retrieval
Number of subjects: 54
Study 12877250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation of sperm retrieved on the day of ovum pickup
Number of subjects: 54
Study 12877250 — intervention group
Group type: COMPARATOR
Intervention: Cryopreservation of sperm retrieved 24 hours before oocyte retrieval
Number of subjects: 54
Study 10750566 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menatetrenone) 45 mg/day orally
Number of subjects: 241
Study 10750566 — intervention group
Group type: COMPARATOR
Intervention: Control (without treatment)
Number of subjects: 241
Study 9363656 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 77
Study 9363656 — intervention group
Group type: COMPARATOR
Intervention: Conventional intermittent mandatory ventilation (CIMV)
Number of subjects: 77
Study 1588147 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP vaccine
Number of subjects: 213
Study 1588147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 3886024 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (12 g/day)
Number of subjects: 24
Study 3886024 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (continued treatment)
Number of subjects: 24
Study 3886024 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched from L-tryptophan)
Number of subjects: 24
Study 3886024 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (increased synthesis of 5-hydroxytryptamine)
Number of subjects: 24
Study 3886024 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (in men)
Number of subjects: 24
Study 3886024 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (in women)
Number of subjects: 24
Study 29921800 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately-high-protein diet
Number of subjects: 147
Study 29921800 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 147
Study 26853287 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lysine (3 g/day)
Number of subjects: 50
Study 26853287 — intervention group
Group type: COMPARATOR
Intervention: Metformin and glibenclamide (standard treatment for both groups)
Number of subjects: 50
Study 24281237 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg testosterone enanthate
Number of subjects: 71
Study 24281237 — intervention group
Group type: COMPARATOR
Intervention: 3 mg testosterone enanthate
Number of subjects: 71
Study 24281237 — intervention group
Group type: COMPARATOR
Intervention: 6.25 mg testosterone enanthate
Number of subjects: 71
Study 24281237 — intervention group
Group type: COMPARATOR
Intervention: 12.5 mg testosterone enanthate
Number of subjects: 71
Study 24281237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 23427401 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuziyanzong treatment (2.30, 4.60, 9.20 g/kg crude drug) for 30 days
Number of subjects: 50
Study 23427401 — intervention group
Group type: COMPARATOR
Intervention: Control group (distilled water)
Number of subjects: 50
Study 20487057 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music 15 min before and during turning
Number of subjects: 17
Study 20487057 — intervention group
Group type: COMPARATOR
Intervention: Control (no music)
Number of subjects: 17
Study 18279551 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (50 mg/d)
Number of subjects: 29023
Study 18279551 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (20 mg/d)
Number of subjects: 29023
Study 18279551 — intervention group
Group type: COMPARATOR
Intervention: Control group (not supplemented with vitamin E)
Number of subjects: 29023
Study 16463853 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar Epidural Pressure (LEDP) monitoring
Number of subjects: 150
Study 16463853 — intervention group
Group type: COMPARATOR
Intervention: Repeated lumbar puncture at 24, 48, 72, and 96 hours
Number of subjects: 150
Study 12848775 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m² with Zosuquidar 3HCl
Number of subjects: 43
Study 12848775 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m² with Zosuquidar 3HCl
Number of subjects: 43
Study 12848775 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone (175 mg/m² or 225 mg/m²)
Number of subjects: 43
Study 10596681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (NOT)
Number of subjects: 76
Study 10596681 — intervention group
Group type: COMPARATOR
Intervention: No NOT (control)
Number of subjects: 76
Study 9124781 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice operation
Number of subjects: 0
Study 9124781 — intervention group
Group type: COMPARATOR
Intervention: Conventional open hernia surgery
Number of subjects: 0
Study 1853691 — intervention group
Group type: EXPERIMENTAL
Intervention: PUR-cannulae
Number of subjects: 37
Study 1853691 — intervention group
Group type: COMPARATOR
Intervention: PTFE-cannulae
Number of subjects: 37
Study 1853691 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro through latex membranes
Number of subjects: 37
Study 6871055 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% prilocaine (4 mg/kg body weight)
Number of subjects: 60
Study 6871055 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% prilocaine (4 mg/kg body weight)
Number of subjects: 60
Study 6871055 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% prilocaine (4 mg/kg body weight)
Number of subjects: 60
Study 30529477 — intervention group
Group type: EXPERIMENTAL
Intervention: EXERCISE NUTRITION
Number of subjects: 38
Study 30529477 — intervention group
Group type: EXPERIMENTAL
Intervention: EXERCISE PLACEBO
Number of subjects: 38
Study 30529477 — intervention group
Group type: COMPARATOR
Intervention: NUTRITION
Number of subjects: 38
Study 30529477 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 38
Study 29446452 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children setting reminders when expecting poorer future memory performance
Number of subjects: 63
Study 29446452 — intervention group
Group type: COMPARATOR
Intervention: Younger children
Number of subjects: 63
Study 27568069 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated PTSD and Smoking Treatment (IPST)
Number of subjects: 80
Study 27568069 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 80
Study 24652692 — intervention group
Group type: EXPERIMENTAL
Intervention: 300,000 IU D₃
Number of subjects: 55
Study 24652692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 21955215 — intervention group
Group type: EXPERIMENTAL
Intervention: MVI ablation only (Group 1)
Number of subjects: 65
Study 21955215 — intervention group
Group type: COMPARATOR
Intervention: Cardioversion and repeat pulmonary vein (PV) isolation plus ablation of non-PV triggers (Group 2)
Number of subjects: 65
Study 20513068 — intervention group
Group type: COMPARATOR
Intervention: Stem cell therapy
Number of subjects: 832
Study 17668881 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 high producer genotype
Number of subjects: 112
Study 17668881 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 low producer genotype
Number of subjects: 112
Study 17668881 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 high producer genotype in acute hepatitis C
Number of subjects: 112
Study 17668881 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 low producer genotype in acute hepatitis C
Number of subjects: 112
Study 17668881 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 high producer genotype in chronic hepatitis C
Number of subjects: 112
Study 17668881 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 low producer genotype in chronic hepatitis C
Number of subjects: 112
Study 15608390 — intervention group
Group type: EXPERIMENTAL
Intervention: Gly/Trp and Trp/Trp genotypes
Number of subjects: 903
Study 15608390 — intervention group
Group type: COMPARATOR
Intervention: Gly460Trp polymorphism
Number of subjects: 903
Study 12234887 — intervention group
Group type: EXPERIMENTAL
Intervention: Entonox
Number of subjects: 20
Study 12234887 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 20
Study 9657656 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta2 agonist (salbutamol) inhalation
Number of subjects: 24
Study 9657656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7907871 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin retard (6 to 18 mg/day)
Number of subjects: 40
Study 7907871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2660284 — intervention group
Group type: EXPERIMENTAL
Intervention: Give-Up Smoking (GUS) kit and quit-smoking advice from their doctor
Number of subjects: 0
Study 2660284 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 29313415 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) plus psychostimulant
Number of subjects: 0
Study 31340800 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Counting (CC)
Number of subjects: 261
Study 31340800 — intervention group
Group type: COMPARATOR
Intervention: MyPlate
Number of subjects: 261
Study 28080169 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMily‐Oriented Support (FAMOS), a home‐based psychosocial intervention delivered in six sessions.
Number of subjects: 68
Study 28080169 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 68
Study 25147236 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1000 mg
Number of subjects: 101
Study 25147236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 23534385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary glycaemic load (GL)
Number of subjects: 1636
Study 23534385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary glycaemic index (GI)
Number of subjects: 1636
Study 21777426 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation (21 sessions)
Number of subjects: 0
Study 21777426 — intervention group
Group type: COMPARATOR
Intervention: Group peer support (21 sessions)
Number of subjects: 0
Study 19689480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG) with extra information and support to parents through group discussions
Number of subjects: 60
Study 19689480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG)
Number of subjects: 60
Study 16092313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (100mg)
Number of subjects: 67
Study 16092313 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 67
Study 10331397 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at rest
Number of subjects: 0
Study 10331397 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion after exercise
Number of subjects: 0
Study 10331397 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise recovery
Number of subjects: 0
Study 10331397 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin effects on glucose uptake and alanine transport
Number of subjects: 0
Study 10331397 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin effects on phenylalanine, leucine, and lysine transport
Number of subjects: 0
Study 8942881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ophthalmic solution 0.3%
Number of subjects: 324
Study 8942881 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (fortified tobramycin 1.3%-cefazolin 5.0%)
Number of subjects: 324
Study 1685323 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine
Number of subjects: 7
Study 1685323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7079905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron plus folic acid
Number of subjects: 41
Study 7079905 — intervention group
Group type: COMPARATOR
Intervention: Intravenous iron‐dextran (Imferon; Fisons)
Number of subjects: 41
Study 31003663 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 120
Study 31003663 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing Awareness (BA)
Number of subjects: 120
Study 31003663 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 29168012 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted RSV prophylaxis
Number of subjects: 0
Study 29168012 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study 27132150 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal impulse and rotor modulation (FIRM) with irrigated radiofrequency (RF) ablation
Number of subjects: 27
Study 24475275 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc intensification
Number of subjects: 0
Study 24475275 — intervention group
Group type: COMPARATOR
Intervention: Non-intensified regimen (Control)
Number of subjects: 0
Study 22237735 — intervention group
Group type: EXPERIMENTAL
Intervention: Carperitide (0.02 g/kg/min, initiated at the start of surgery and continued for ≥5 days)
Number of subjects: 88
Study 22237735 — intervention group
Group type: EXPERIMENTAL
Intervention: Carperitide
Number of subjects: 88
Study 22237735 — intervention group
Group type: COMPARATOR
Intervention: Control (no carperitide)
Number of subjects: 88
Study 19719746 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.01 mg/kg)
Number of subjects: 11
Study 19719746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 17611417 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardasil immunization
Number of subjects: 0
Study 17611417 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 18 L1 VLP immunization
Number of subjects: 0
Study 16338245 — intervention group
Group type: EXPERIMENTAL
Intervention: fondaparinux
Number of subjects: 20000
Study 16338245 — intervention group
Group type: COMPARATOR
Intervention: early angiography and intervention
Number of subjects: 20000
Study 11978253 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 416
Study 11978253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 9535143 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-alcohol beer (0.9% vol:vol)
Number of subjects: 55
Study 9535143 — intervention group
Group type: COMPARATOR
Intervention: Full-strength beer (5% vol:vol)
Number of subjects: 55
Study 7635541 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous phenylephrine
Number of subjects: 8
Study 7635541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroprusside
Number of subjects: 8
Study 7635541 — intervention group
Group type: COMPARATOR
Intervention: Finapres measurements during high-dose intravenous phenylephrine
Number of subjects: 8
Study 7635541 — intervention group
Group type: COMPARATOR
Intervention: Finapres measurements during intravenous nitroprusside
Number of subjects: 8
Study 7635541 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional infusion of phenylephrine
Number of subjects: 8
Study 7635541 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional infusion of nitroprusside
Number of subjects: 8
Study 2551565 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 20
Study 2551565 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 20
Study 31845837 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone, dihydrotestosterone, and androstenedione
Number of subjects: 335
Study 31845837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone, 5alpha‐androstan‐3beta,17beta‐diol, androstenediol, and androsterone
Number of subjects: 335
Study 31845837 — intervention group
Group type: EXPERIMENTAL
Intervention: Extragonadal steroids
Number of subjects: 335
Study 31845837 — intervention group
Group type: EXPERIMENTAL
Intervention: Total androgen receptor transcriptional activity secondary to testosterone, dihydrotestosterone, and androstenedione
Number of subjects: 335
Study 31845837 — intervention group
Group type: EXPERIMENTAL
Intervention: Extragonadal androstenedione
Number of subjects: 335
Study 30693610 — intervention group
Group type: EXPERIMENTAL
Intervention: Family activities for children with developmental delay
Number of subjects: 49
Study 30693610 — intervention group
Group type: COMPARATOR
Intervention: Typically developing children
Number of subjects: 49
Study 27592696 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (TIV)
Number of subjects: 124
Study 27592696 — intervention group
Group type: COMPARATOR
Intervention: Control (hepatitis A vaccine)
Number of subjects: 124
Study 25629819 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the mobile application
Number of subjects: 202
Study 25697247 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological saline enemas with glycerol (0.8 ml glycerol + 3 ml saline or 1 ml glycerol + 5 ml saline)
Number of subjects: 101
Study 25697247 — intervention group
Group type: COMPARATOR
Intervention: Simulation (control group)
Number of subjects: 101
Study 25697247 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological saline enemas with glycerol
Number of subjects: 101
Study 22806274 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (two different dose regimens)
Number of subjects: 0
Study 22806274 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 20236380 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched YAG laser treatment (Q-YAG 5 system, 1064 nm, Palomar Inc., Burlington, VT, USA); series of three treatments at 6-week intervals.
Number of subjects: 10
Study 20236380 — intervention group
Group type: COMPARATOR
Intervention: Punch biopsy excision; one treatment.
Number of subjects: 10
Study 17996094 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminectomy with dorsal fusion
Number of subjects: 60
Study 17996094 — intervention group
Group type: COMPARATOR
Intervention: Laminectomy without dorsal fusion
Number of subjects: 60
Study 15791439 — intervention group
Group type: EXPERIMENTAL
Intervention: [99mTc]TRODAT‐1 SPECT binding in MSA patients
Number of subjects: 203
Study 15791439 — intervention group
Group type: EXPERIMENTAL
Intervention: [99mTc]TRODAT‐1 SPECT binding in PD patients
Number of subjects: 203
Study 15791439 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 203
Study 15791439 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior putamen DVR in MSA patients
Number of subjects: 203
Study 12088160 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (mean final dose = 466 mg/day)
Number of subjects: 597
Study 12088160 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (mean = 16.0 sessions)
Number of subjects: 597
Study 12088160 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nefazodone (mean dose = 460 mg/day) and CBASP (mean = 16.2 sessions)
Number of subjects: 597
Study 9827437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of baclofen (initially 156 μg/24 hours, increased to 280 μg/24 hours)
Number of subjects: 60
Study 9827437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of baclofen
Number of subjects: 60
Study 7896977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 0
Study 7896977 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 0
Study 7896977 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 7896977 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 2559484 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin (2,500 anti Xa units, subcutaneously, once daily for 5-9 days)
Number of subjects: 183